BBH - Biotechnology story continues
This is a Continued analysis of the Biotech sector
Since many are now worried about inflation, high prices in the commodity sector, and growing stock indices. I believe that the Biotech sector will be weak this year.
The sector will receive less than one share of funding and will most likely begin to recover only by the end of Biden's presidential term.
I consider the current prices near $ 215-225 per share of this ETF to be an excellent opportunity to open a short position. This will be a 4-fold increase from the beginning of the wave and it is likely that we will set a maximum for now.
Drivers for the sector's growth are possible indulgences from the FDA or the beginning of the approval of new regulations. As well as the recovery of the reporting season and mergers.
The driver for the decline is the current market conditions. Risk assets, such as Biotech shares, will be the first to get rid of. We are already seeing a significant increase in cash on the balances of large players, as well as an increase in baby backs. Which suggests that such high-risk stories are not attractive yet.
Speculation consists in a short position from the current levels with a stop at 250, and profits with targets at 175 and 130 for this ETF. You can also look at the related idea posted earlier.
Profit for everyone
Since many are now worried about inflation, high prices in the commodity sector, and growing stock indices. I believe that the Biotech sector will be weak this year.
The sector will receive less than one share of funding and will most likely begin to recover only by the end of Biden's presidential term.
I consider the current prices near $ 215-225 per share of this ETF to be an excellent opportunity to open a short position. This will be a 4-fold increase from the beginning of the wave and it is likely that we will set a maximum for now.
Drivers for the sector's growth are possible indulgences from the FDA or the beginning of the approval of new regulations. As well as the recovery of the reporting season and mergers.
The driver for the decline is the current market conditions. Risk assets, such as Biotech shares, will be the first to get rid of. We are already seeing a significant increase in cash on the balances of large players, as well as an increase in baby backs. Which suggests that such high-risk stories are not attractive yet.
Speculation consists in a short position from the current levels with a stop at 250, and profits with targets at 175 and 130 for this ETF. You can also look at the related idea posted earlier.
Profit for everyone
פרסומים קשורים
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.